Abstract 5550
Background
Mps1 is a serine threonine kinase and a core component of the spindle assembly checkpoint. Two potent, selective, and orally active Mps1 inhibitors -- BAY 1161909 (BAY; lead compound) and BAY 1217389 -- have shown improved efficacy in combination with paclitaxel (Pac) in xenograft models, including Pac-insensitive and acquired resistance models. We report here on the safety, tolerability, and maximum tolerated dose (MTD) of the lead compound BAY in combination with Pac.
Methods
Subjects with advanced malignancies (solid tumors) and refractory to standard therapy were eligible. BAY was administered twice daily (BID) in a 2-days on/5-days off dosing schedule in combination with weekly IV Pac starting at 75 mg/m2 (Pac-75), and then at 90 mg/m2 (Pac-90). The dose of BAY was doubled in sequential cohorts until the MTD was reached. Pharmacokinetic analyses were done to determine exposure of BAY and Pac.
Results
A total of 37 patients were enrolled and treated in the Pac-75 cohort and 32 in the Pac-90 cohort, with median age 60 in both groups. Breast, NSCLC, and ovarian adenocarcinomas were the most common cancers. The majority of patients (53.6%) had >3 prior lines of anticancer therapy. BAY exposure generally increased in a dose proportional manner and did not affect Pac exposure. In BAY plus Pac-75 cohorts, 16% of patients had grade (G) 3 BAY-related adverse events (AEs), with no G4/G5 events. In the Pac-90 cohorts, 28% of patients had G3 events, one G4 and no G5 BAY-related events. The most common treatment emergent AEs were fatigue (44.9%), anemia (39.1%), alopecia (37.7%), diarrhea (34.8%) and nausea (33.3%). In 35 evaluable patients from the BAY plus Pac-75 group, there were 5 (14%) PRs, 11 SD,17 PD, and 2 patients not determined. In 28 evaluable patients in the BAY plus Pac-90 group, there were 4 (14%) PRs, 13 SD, and 11 PD. Six of 9 patients with a PR had prior Pac. One dose limiting toxicity (ALT increased) was reported in the BAY 180 mg BID plus Pac-90 dose cohort. The MTD was determined as BAY 90 mg BID plus Pac-90.
Conclusions
BAY in combination with Pac demonstrated good tolerability with manageable AEs and preliminary evidence of efficacy. Study with the follow-up compound BAY 1217389 is ongoing.
Clinical trial identification
NCT02138812.
Legal entity responsible for the study
Bayer AG.
Funding
Bayer AG.
Editorial Acknowledgement
Disclosure
P. Rajagopalan, C. Cyris, I. Bruns, J. Mei, F. Souza: Employment: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract